The Bimonthly European Industrial Pharmacists' Newsletter

OCTOBER 2025

Business & Policies

The challenging roadmap to design the future of EU's R&D

Roadmap for the EU's post-2027 R&I programme: ERC criticizes limited simplification, while dual-use technologies and "moonshot" projects aim to boost Europe's competitiveness.

Regulatory Affairs

Consultation open on the revision of GMP's Chapter 1

The EU Commission has opened a consultation (until 3 Dec 2025) on revising GMP Chapter 1 – "Pharmaceutical Quality System". The draft integrates ICH Q9(R1) principles on risk management and knowledge, strengthening quality culture and product review.

Sustainability & Environment

Pharmaceuticals in the environment, the report of the Ad Hoc Working Group

EMA's horizon scanning report on New Approach Methodologies (NAMs) highlights emerging tools and technologies aimed at reducing animal testing, accelerating drug development, and supporting regulatory innovation.

Artificial Intelligence

The EU Commission's Study on the deployment of AI in healthcare

The European Commission's August 2025 study on AI in healthcare explores how AI can boost operational efficiency, diagnostics and treatment pathways, but also warns of major hurdles such as data interoperability, regulatory complexity and trust.

Magazine MakingLife

ATMP

In the new issue of MakingPharmaIndustry Magazine, we explore the evolution of Advanced Therapies—from market growth and sustainability to the latest EMA guidelines. From research to production, and through the impact of artificial intelligence, a journey inside the factories and economic models redefining the value of care.

Webinar

Accelerating Clinical Trials in the EU, ACT-EU and the role of the Multi-stakeholder Platform

EIPG webinar with Rebecca Stanbrook (Novartis) on November 17 at 17:00 CET. Focus on the ACT-EU initiative and the role of the Multi-Stakeholder Platform in shaping the future of clinical trials in Europe. Register here.